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Depression is a debilitating disorder that can cause motivational deficits such as psychomotor 
retardation, anergia, apathy, and fatigue. Recent research indicates that these motivational 
deficits, and potential pathways of therapeutic intervention, can be studied in animal models 
involving rats and mice. Treatments with the VMAT-2 inhibitor tetrabenazine (TBZ) and 
cytokine interleukin-1ß (IL-1ß) can create a low-effort bias and impair effort-related motivation 
(Nunes et al. 2013, 2014).  A number of high-affinity DA transport inhibitors such as d-
amphetamine, methylphenidate, and cocaine can restore extracellular DA, albeit with the cost of 
undesirable effects such as high abuse liability. These observations have led researchers to 
identify a number of molecules that fit the profile of “atypical” dopamine binding, which leads to 
a longer duration of extracellular DA and minimizes side effects. In this review, the binding 
affinities and dose-response behavioral outputs for respective FR5/Chow and PROG/Chow 
feeding procedures have been compiled for eight DAT blockers: bupropion, GBR12909, 
lisdexamfetamine, PRX-14040, modafinil, (S)-CE-123, (S, S)-CE-158, and methylphenidate. 
Regression analyses between measures of DAT affinity and minimum significant dose in 
behavioral studies suggests a strong linear relationship between binding affinity and potency in 
terms of the ability of drugs to reverse the effects of TBZ the FR5/chow procedure. However, 
there was a variable relationship in terms of the ability of drugs to enhance lever pressing in rats 
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Motivated behavior is recognized to have directional aspects (i.e., behavior is directed towards 
and away from stimuli), but it also has activational aspects related to behavioral activation and 
exertion of effort in work output. Organisms often make effort-based decisions as they weigh the 
costs and benefits of the various options in the environment. One of the ways that effort-related 
aspects of motivation can be assessed is through tests of effort-based choice, in which animals 
are given a choice between a preferred reinforcer that can only be obtained by high exertion of 
effort, vs. a low effort/low reward option. Studies have shown that the vesicular monoamine 
transport (VMAT-2) inhibitor tetrabenazine (TBZ) or the cytokine interleukin-1β (IL-1β) can 
cause profound motivational impairments and shift choice behavior in rats, producing a low-
effort bias (Nunes et al., 2013; Yohn et al. 2016). TBZ acts by blocking vesicular storage and 
depleting dopamine (DA), as assessed by both pre- and postsynaptic markers of DA transmission 
(Nunes et al. 2013). In fact, the effects of TBZ in humans can even result in the emergence of 
negative symptoms such as fatigue, pointing to its potential in creating a challenge for rats to 
exert physical effort when presented with a choice (Chitnis and Karunapuzha, 2009; Frank, 
2010; Chen et al., 2012; Rotolo et al., 2020). In response to TBZ administration, rats demonstrate 
a decreased selection of the high effort options and increased selection in low effort/low energy 
options. This is possibly related to the induction of depression-like symptoms. Using an FR5 or 
PROG chow feed task model, the behavioral outputs of several 5-HT selective serotonin 
reuptake inhibitors (SSRI) and DA transport (DAT) inhibitors can be studied for a potential 
reversal of the effects of TBZ (Yohn et al. 2016).  
Rats have become a useful model organism to test the effects of commonly prescribed 
antidepressants that are SSRIs, such as Lexapro (S-citalopram) and Prozac (fluoxetine), which 
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are typical treatments of depression and generalized anxiety. Recent FR5 and PROG chow feed 
task trials with (S)-citalopram and fluoxetine, however, have yielded no significant reversal of 
the effects of TBZ (Salamone et al. 2018). In fact, these serotonin transport inhibitors even have 
the tendency to exacerbate symptoms and produce further impairments in level pressing such as 
fatigue (Yohn et al., 2016). These data point to the inefficiency of common market SSRIs in 
battling motivational symptoms in patients. Since SSRIs selectively inhibit serotonin reuptake 
pathways, research suggests that the dopamine transporter is associated with a critical pathway in 
cost/benefit analysis and effort-related decision making (Nunes et al., 2013; Yohn et al. 2016). 
A number of DAT inhibitors have been tested by Salamone and colleagues (Nunes et al. 2013; 
Randall et al. 2015; Yohn et al. 2016; Rotolo et al. 2019, 2020, 2021). For the present study, a 
select number of reversal agents that directly act on the nucleus accumbens core DA transporter 
were investigated for their respective binding affinities and dose-response outputs (Salamone and 
Correa, 2002, 2012; Salamone et al, 2003, 2007; Nunes et al, 2013). These DAT inhibitors 
(bupropion, GBR12909, lisdexamfetamine, PRX-14040, modafinil, (S)-CE-123, (S, S)-CE-158, 
and methylphenidate) are all highly selective for DAT binding relative to the serotonin 
transporter, and some are selective vs. norepinephrine transport binding as well. Affinity more 
specifically refers to the strength of the tendency of a neurotransmitter or ligand to bind to its 
protein target, whether a receptor or a transporter. Intrinsic quantitative measures such as Ki, 
Km, Kapp or IC50 can represent affinity as the concentration of a ligand that yields 50% of 
maximal transporter binding. Transporter binding is central to determining drug affinity for 
drugs that act on the uptake process, yet potency in terms of behavioral effects incorporates other 
factors such as metabolism, penetration into the tissue of interest, and the duration of action. The 
doses at which a drug has its effect and its molecular affinity are typically correlated as long as 
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these other factors are relatively equal, so the present study seeks to identify a link for each DAT 
inhibitor on both FR5 and PROG operant procedures. After compiling DAT binding affinity 
(nM) values and calculating lowest significant doses (mg/kg) for behavioral effects in rats tested 
on FR5 and PROG procedures, a statistical regression analysis was conducted to determine the 
line of best fit and the Pearson product-moment correlation coefficient, the proportion of 
variability accounted for, and the standard error of estimate around the regression line. These 
analyses can be used to further clarify the relation between binding to the DAT as measured in 
vitro and the behavioral effects of these drugs.  
 
Materials and Methods  
Animals 
For the behavioral studies (Nunes et al. 2013; Randall et al. 2015; Yohn et al. 2016; Rotolo et al. 
2019, 2020, 2021), protocols were approved by the University of Connecticut Institutional 
Animal Care and Use Committee (IACUC). Adult male Sprague Dawley rats (Indianapolis, IN, 
USA) were housed at 23 °C during 12 hour light/dark cycles (e.g. Yohn et al., 2016). The 
animals generally weighed approximately 300 grams at the beginning of each study. Although 
initially, food was restricted to 85% of their body weight, these rats were later fed supplemental 
lab chow and provided water ad libitum to allow gradual growth. Animal protocols followed 
National Institute of Health (NIH) guidelines (e.g. Nunes et al., 2013). 
 
Concurrent FR5/Chow-choice Procedure 
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The concurrent FR5/chow-choice procedures were conducted in operant conditioning chambers, 
where rats were first trained to lever press with continuous reinforcement. These sessions were 
generally 30 minutes over 5 days, after which the rats were shifted to an FR5 schedule (30 min 
sessions, 5 days/week). After training for several weeks until reaching a baseline target for lever 
presses, the rats were finally introduced to the concurrent FR5/chow feeding choice procedure. 
This procedure is conducted in the operant chamber by making a low-reward lab chow and a 
high-carbohydrate reinforcer accessible via lever pressing during the 30-minute session. While 
both options are available, the rats are able to choose their behavior towards either the chow or 
the high carb pellet. Before starting the session, it was ensured that the weighted chow pieces 
would not fall through the floor of the chamber (e.g. Rotolo et al., 2019). At the start of each 
session, it was confirmed that the pieces of weighed chow were larger than the spaces between 
the bars that make up the floor of the chamber, so they could not fall through. After each session 
completed, each rat was removed from the chamber while the number of lever presses and 
consumed chow weight (calculated from spillage) was recorded (e.g. Yohn et al., 2016). 
 
PROG/Chow Feeding Choice Task  
In contrast to the concurrent FR5 procedure, the lever-pressing option will end in the 
PROG/chow-feeding choice procedure within 2 minutes if the rat fails to obtain a reinforcer, 
meaning that the chow will become the only option after this interval (Salamone et al., 2018). 
This “time-out” would result from the deactivation of the response lever for the rest of the 
session when the 2-minute interval completed without a completed ratio (Rotolo et al., 2019). 
For this procedure, rats were first trained on a continuous reinforcement FR1 schedule followed 
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by a shift to a PROG schedule, where the ratio from the FR1 was gradually increased. After 
several weeks of training on the PROG schedule, weighted amounts of lab chow become 
available in the chamber during PROG/chow feeding choice task sessions (generally 30 minutes 
each). Similar to the FR5 procedure, the number of lever presses and amount of chow consumed 
were recorded at the end of each session. After training on the concurrent FR5/chow-choice and 




Novel atypical molecules obtained by Salamone Lab were generally dissolved in dimethyl 
sulfoxide (DMSO) and saline solution with the DMSO/saline solution serving as vehicle control, 
or in physiological saline. Tetrabenazine was received from Tocris Bioscience (Ellisville, MO) 
and titrated with extremely small quantities of 1.0 N HCl to achieve an overall pH of 4.5. The 
dosage of TBZ was typically calculated to be 0.75 mg/kg-1.0 mg/kg TBZ based on extensive 
piloting and previous work in the laboratory.  Doses of reversal agents were also determined 
based on previous research and rodent runaway studies (Sink et al., 2008; Esumi et al., 2013). 
 
Statistical Analysis 
DAT affinity values were extensively searched through neuropsychopharmacology literature 
using the electronic database PubMed, as listed in Table 1. These data were calculated via in 
vitro binding or inhibition assays (Cao et al., 2016; Zhang et al., 2017). In each behavioral 
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pharmacology paper, rats received vehicle or 0.75mg/kg TBZ approximately 90 minutes before 
testing followed by intraperitoneal injections of vehicle or the DAT blocker at varying times 
before behavioral testing, depending upon the drug (Salamone et al., 2016; Rototol et al. 2019, 
2020, 2021).  Statistical analyses were used in each paper to identify the doses of a DAT blocker 
plus TBZ that significantly increased lever pressing relative to TBZ plus vehicle (P<0.05). The 
potency values for the regression analyses for each DAT inhibitor were calculated by identifying 
the lowest significant dose based on the minimum dosage that significantly differed from TBZ 
plus vehicle. A complete list of binding affinity (nM) and lowest significant doses (mg/kg) for all 
eight DAT blockers used in the TBZ studies is depicted in Table 2. GraphPad Prism 8.4.1 was 
used to compute a regression analysis determining a linear relationship between affinity and 
potency for both concurrent FR5 and PROG chow choice procedures (Figure 1). Recently 
synthesized atypical DAT inhibitor CT-005404 (Chronos Therapeutics) was excluded from this 
study as doses were administered orally rather than intraperitoneally (Rotolo et al., 2020). 
Modafinil was studied for its effects on FR5/chow feeding choice performance but never for its 
ability to reverse choice-induced shifts of TBZ on the PROG/chow feeding procedure (Salamone 
et al., 2016). For this reason, it was included in the DAT vs. FR5 statistical analysis (n=8) but 




The commonly prescribed antidepressant bupropion was extensively studied in the Nunes et al. 
2013 study with IP injections of Vehicle/Vehicle, 0.75 mg/kg TBZ/Veh, or TBZ coadministered 
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with doses of bupropion (5.0, 10.0, or 15.0 mg/kg doses). Compared to the administration of 
TBZ alone, catecholamine uptake inhibitor bupropion was able to significantly reverse the 
effects of tetrabenazine. The highest doses of bupropion increased lever presses over a 30-minute 
session and decreased intake of freely available laboratory chow. 
In the Yohn et al. 2016 study, however, the selective DA D1 antagonist SCH 39166 (ecopipam) 
and DA D2 antagonist haloperidol were capable of blocking its reversal of TBZ depressive 
effects. Although these antagonists had no effects when administered alone, the coadministration 




Originally developed as a potential treatment for cocaine addiction, GBR12909 shows a much 
lower efficacy than cocaine and atypical binding properties (Yohn et al., 2016). More than a 100-
fold lower in NET and SERT affinity (Anderson, 1989), GBR12909 is one of many benztropine 
analogs that have been associated with increased DA levels in nucleus accumbens for a longer 
duration than cocaine. In an experiment in the Yohn et al. 2016 study, trained rats received the 
following treatments of TBZ vehicle plus GBR12909 vehicle: 0.75 mg/kg TBZ + GBR12909 
vehicle, 0.75 mg/kg TBZ + 1.25 mg/kg GBR12909, 0.75 mg/kg TBZ + 2.5 mg/kg GBR12909, 
and 0.75 mg/kg TBZ + 5.0 mg/kg GBR12909. The results showed that the highest doses of 
GBR12909 + TBZ vehicle (2.5 and 5.0 mg/kg of GBR12909) were statistically significant 
(P<0.05) from the TBZ vehicle, leading to a significantly lower chow consumption. 
Additionally, when administered without TBZ on a concurrent FR5/chow-choice procedure, the 
highest doses of GBR12909 yielded significantly higher lever presses than NET inhibitor 
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desipramine and SERT inhibitor fluoxetine. The results of this study demonstrate that 
GBR12909 successfully attenuates TBZ-induced shifts in rat behavior, and it is a more powerful 
reversal agent than norepinephrine and serotonin transport inhibitors. 
 
LDX 
Lisdexamfetamine (LDX) is a novel descendant of d-amphetamine which has been approved for 
the treatment of attention deficit hyperactivity disorder (ADHD) and binge eating disorder in 
adults (Weisler et al. 2009; FDA News Release 2015). While d-amphetamine is known to cause 
sudden bursts in extracellular catecholamine levels, LDX leads to a much longer duration of 
these neurotransmitter levels, especially high concentrations of dopamine in the nucleus 
accumbens. The ability of LDX to increase effort in rats treated with cytokine interleukin-1ß, 
TBZ, and TBZ + CIT was studied on a concurrent FR5/chow-feeding procedure. IL-1ß is 
associated with depressive symptoms in humans and has shown to reduce the selection of high 
effort alternatives and increase consumption of lab chow in rat models. In the Yohn et al. 2016 
study of LDX, the ability of LDX to ameliorate the effects of IL-1ß was experimented with the 
following dosage: IL-1β-vehicle + LDX vehicle, 4.0 μg/kg IL-1β- + LDX vehicle, 4.0 μg/kg IL-
1β- +0.09375 mg/kg LDX, 4.0 μg/kg IL-1β- + 0.1875 mg/kg LDX, 4.0 μg/kg IL-1β- + 0.375 
mg/kg LDX, and 4.0 μg/kg IL-1β- + 0.75 mg/kg LDX. The treatment of 0.09, 0.375 and 0.75 
mg/kg of LDX with IL-1ß significantly increased lever pressing and decreased chow 
consumption compared to IL-1ß alone. Similarly, the ability of LDX to attenuate the behavioral 
effects of TBZ treatment was investigated on the same procedure with the following dosage: 
TBZ vehicle + LDX vehicle, 0.75 mg/kg TBZ + LDX vehicle, 0.75 mg/kg TBZ + 0.09375 
mg/kg LDX; 0.75 mg/kg TBZ + 0.1875 mg/kg LDX, 0.75 mg/kg TBZ + 0.375 mg/kg LDX, and 
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0.75 mg/kg TBZ + 0.75 mg/kg LDX. Similar to the results of the IL-1ß experiment, LDX 
successfully attenuated the effects of TBZ with the coadministration of 0.1875, 0.375, and 0.75 
mg/kg LDX being statistically significant (P<0.05). In all three treatments, LDX plus TBZ 




Novel DA update inhibitor PRX-14040 was introduced as a transporter with low molecular 
weight and Log P values yet an optimal atypical DA selectivity. While PRX is able to bind to 
both dopamine and norepinephrine transporters, it shows a 28-fold higher selectivity for the 
dopamine transporter (Yohn et al., 2016). The Yohn et al. (2016) PREXA study analyzed the 
ability of PRX to both reverse the TBZ shifts in behavior on the FR5/chow choice task and 
increase lever pressing in the PROG/chow choice task. On the FR5 procedure, trained rats 
received the following dosage: TBZ vehicle + PRX vehicle, 0.75 mg/kg TBZ + PRX vehicle, 
0.75 mg/kg TBZ + 1.25 mg/kg PRX, 0.75 mg/kg TBZ + 2.5 mg/kg PRX, 0.75 mg/kg TBZ + 5.0 
mg/kg PRX, and 0.75 mg/kg TBZ + 10.0 mg/kg PRX. Overall, PRX yielded a complete reversal 
of the effects of TBZ with the co-administration of 2.5, 5.0, and 10.0 mg.kg PRX significantly 
increasing the number of lever presses and increasing chow consumption relative to the TBZ 
vehicle group (P<0.0001). In the PROG/chow choice task, trained rats were IP injected with 
doses of 5.0, 10.0, 20.0, and 40.0 mg/kg PRX an hour before testing. The results revealed that 
the administration of 10.0, 20.0 and 40.0 mg/kg PRX significantly increased the total number of 
lever presses, achieved the highest ratio relative to vehicle treatment (F(4.36) = 12.075), and 
decreased consumption of lab chow (P<0.05). PRX also yielded the highest reversal effect size 
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(partial ε2) for TBZ-induced reversal of suppression in lever pressing and increase in chow 
intake relative to bupropion, modafinil and methylphenidate. The unique DA binding selectivity 
of PRX, compared to other drugs such as BUP, MOD, and MET, improves its candidacy as a 
treatment of motivational dysfunction. 
 
Modafinil 
Modafinil, or MOD, is a wakefulness agent that has already been used in clinical studies to treat 
depressive-like symptoms such as fatigue and anergia. The Rotolo et al. 2019 study compared 
modafinil to its analog (S)-CE-123. While MOD demonstrates improvement in fatigue and 
reversal of low-effort bias, it requires higher doses on the FR5 procedure than analogs with 
highly selective DA binding. Despite its low affinity in the reversal of depressive symptoms, 
MOD demonstrates a low abuse liability. As mentioned earlier, modafinil was not tested for its 
potential to reverse effects of TBZ on the PROG procedure.  
 
(S)-CE-123 
Novel atypical DA transport inhibitor (S)-CE-123 is a synthesized analog of modafinil with a 
highly selective affinity for DAT. The Rotolo et al. 2019 study has not only demonstrated its 
ability to reverse TBZ-induced shifts in rats, but also its enhancement of cognitive flexibility and 
reduction of impulsivity and undesirable effects. In the study, trained rats were administered the 
following combinations of (S)-CE-123 and TBZ: TBZ vehicle + (S)-CE-123 vehicle, 1.0 mg/kg 
TBZ + (S)-CE-123 vehicle, 1/0 mg/kg TBZ + 6.0 mg/kg (S)-CE-123, 1.0 mg/kg TBZ + 12.0 
mg/kg (S)-CE-123, and 1.0 mg/kg TBZ + 24.0 mg/kg (S)-CE-123. The coadministration of 24.0 
mg/kg (S)-CE-123 significantly increased total lever presses and decreased chow consumption. 
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Although the administration of (S)-CE-123 alone had no effect on lever pressing or chow 
consumption, it significantly increased the DA levels in the nucleus accumbens core (P<0.05). 
 
(S, S)-CE-158 
(S, S)-CE-158 is a novel atypical analog of modafinil, similar to its stereoisomer, thiazole-based 
(S)-CE-123, in its specificity of its DA inhibition. While (S)-CE-123 has demonstrated pro-
cognitive effects and preclinical effectiveness without adverse side effects, (S, S)-CE-158 and a 
range of modafinil-related drugs have been included in the investigation to identify the most 
promising candidate to treat motivational dysfunction (Nikiforuk et al. 2017; Kalaba et al. 2017; 
Kristofova et al. 2018; Camats-Perna et al. 2019). In the Rotolo et al. 2020 study, rats were 
administered five treatment options: TBZ vehicle + (S, S)-CE-158 vehicle; 1.0 mg/kg TBZ + (S, 
S)-CE-158 vehicle; 1.0 mg/kg TBZ + 2.0 mg/kg (S, S)-CE-158; 1.0 mg/kg TBZ + 4.0 mg/kg (S, 
S)-CE-158; 1.0 mg/kg TBZ + 8.0 mg/kg (S, S)-CE-158. The co-administration of 8.0 mg/kg (S, 
S)-CE-158 plus TBZ yielded a significant increase in lever pressing and decrease in chow intake 
compared to TBZ plus vehicle (P<0.001). Repeated measures ANOVA identified a significant 
increase in lever pressing and high-effort responding on the concurrent PROG/chow feeding 
choice procedure at a co-administered minimum dose of 4.0 mg/kg (S, S)-CE-158 plus TBZ 
compared to TBZ plus vehicle (P<0.01). 
Methylphenidate 
Methylphenidate, or MET, is a stimulant drug with DA reversal properties that has been 
commonly tested in human clinical populations. In the Yohn et al. 2016 PREXA study, the co-
administration of MET with TBZ in rats successfully attenuated the effects of TBZ alone, but it 
resulted in similar comparisons as modafinil. Compared to the co-administration of PRX and 
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BUP, MET yielded significantly lower lever presses on the FR5 procedure. Although 
methylphenidate improves motivational deficits by inhibiting the dopamine transporter (DAT), 
its stimulant nature also results in a number of undesirable side effects such as strong abuse 
liability and psychotic symptoms (Rotolo et al., 2019). 
 
DAT Blocker Affinity Value Citation 
Bupropion Ki = 630nM (Meyer et al., 2002; Richelson 
and Pfenning 1984; Tatsumi 
et al. 1997; Schmitt et al., 
2008) 
GBR12909 Kapp = 121∓ 21nM (Schmitt et al., 2008; 
Vladimir et al., 2008) 
LDX Km = 200nM (Yohn et al., 2016) 
PRX-14040 Ki = 9.43nM (Yohn et al., 2016; Gu et al., 
1994; Giros and Caron, 1993; 
Galli et al., 1995; Shearman 
et al., 1998) 
Modafinil Km = 3050 ∓ 258nM (Salamone et al., 2016; Zhang 
et al. 2017) 
(S)-CE-123 IC50 = 4.6 µM (Sagheddu et al., 2020) 
(S, S)-CE-158 IC50 = 0.2271μM (Rotolo et al., 2020) 
Methylphenidate IC50  = 224 ∓ 19nM (Salamone et al., 2016; 
Wayment et al., 1999) 
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Table 1. List of dopamine transport inhibitors from selective literature and corresponding 
affinity values (nM). 
 FR5 (mg/kg) DAT (nM) PROG (mg/kg) 
BUP 10 630 20 
GBR12909 2.5 121 5 
LDX 0.1875 200 0.75 
PRX-14040 2.5 9.43 20 
MOD 7.5 3050  
(S)-CE-123 24 4606 24 
(S, S)-CE-158 8 227 4 
METH 0.5 224 4 
BUP = bupropion; LDX = lisdexamfetamine; MOD = modafinil; METH = methylphenidate 
Table 2. List of lowest effective doses (mg/kg) calculated from FR5 and PROG dose-response 
curves and corresponding DAT affinities (nM). 
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Figure 1. A) Scatterplot with regression line (solid line) and 95% confidence intervals (dotted 
curves) showing the relation between affinity of DA transport blocker vs. its minimum effective 
dose on concurrent FR5/Chow-choice Procedure. R2 = 0.7089 and the graph has a 95% 
confidence interval of (0.3376, 0.9707) with a standard error of estimate (sYX) of 4.599. B) 
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Scatterplot with regression line (solid line) and 95% confidence intervals (dotted curves) 
showing the relation between affinity of dopamine transport blocker against its minimum 
effective dose on PROG/Chow Feeding Choice Task. R2 = 0.3687 and the graph has a 95% 
confidence interval of (-0.2687, 0.9334) with a sYX of 8.483. 
 
Discussion 
In determining the “goodness of fit” on a correlational analysis, the coefficient of determination 
(R2) and standard error of estimate (sYX) are common indicators. Variance, or the scatter around 
the line of best fit, refers in this study to the minimum dose values (mg/kg) that can be predicted 
by DAT affinity values (nM). The R2  calculations of both graphs indicate that 71% of the 
variance in data can be explained in the concurrent FR5 procedure (Figure 1A), yet only 37% 
can be explained in the concurrent PROG procedure (Figure 1B). The 95% confidence bands 
also demonstrate a larger gap in variance on the PROG interval of (-0.2687, 0.9334) compared to 
the FR5 interval of (0.3376, 0.9707). The standard error of estimate, or sYX, measures both the 
variability of the observed scatter and reliability of the estimating equation (Y=mx+b). The 
predicted sYX value for DAT vs FR5 is 4.599, nearly half the DAT vs PROG value of 8.483. 
The strength of the correlation between affinity and behavioral potency can be characterized with 
significantly less dispersion on the FR5 procedure relative to the PROG procedure. 
The Pearson product-moment correlation coefficient (r) captures linear relationships on a range 
of -1 to +1, corresponding to negative and positive slopes respectively. An absence of a linear 
pattern falls closer to a value of 0. GraphPad Prism 8.4.1 computed r = 0.8420 for Figure 1A and 
r = 0.6072 for Figure 1B, indicating stronger linearity on the FR5 procedure relative to the 
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PROG procedure. A computational two-tailed hypothesis test (α = 0.05) yielded a p-value of 
0.0087 for DAT vs FR5 and a p-value of 0.1482 for DAT vs PROG. For the regression graph of 
FR5, P<0.05 and the null hypothesis can be rejected, concluding a strong linear correlation 
between the variables. The PROG data, however, fails to reject Ho in favor of Ha (P>0.05) and 
lacks substantial evidence to conclude a linear relationship. The correlation between the dose at 
which a DAT blocker has its effect and its unique binding affinity can be summarized as 
statistically significant for the FR5/chow choice task, but not conclusive for the PROG/chow 
choice task. 
The increased variability in PROG dispersion compared to that of the FR5 procedure could be 
partially attributed to its exclusion of modafinil, reducing its total drug count to n = 7. The drugs 
selected for this study consist of both typical and atypical DA transport blockers. Atypical 
analogs of modafinil such as (S)-CE-123 and (S, S)-CE-158 indicate a better profile for reversing 
depression-like symptoms while decreasing potential side effects. In addition to DAT affinity, 
the selectivity and binding locus of a DAT blocker have profound effects on DAT trafficking and 
the ability to reduce abuse liability and psychotic symptoms (Rotolo et al., 2019). The correlation 
in this study is strictly between drug affinity and potency; there is no noticeable distinction based 
on binding selectivity.  
In summary, there is a strong relationship between the concentration at which these various DAT 
inhibitors affect DA transport in vitro and the doses at which the same compounds reverse the 
effects of TBZ in vivo in rats responding on the FR5/chow feeding choice task. However, the 
results regarding the PROG task were inconclusive.  Future studies may consider drafting more 
candidates for the regression analysis on the PROG procedure and investigating differences 
between atypical or typical binding in relation to potency. Ongoing research on this topic could 
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provide insight on dosage in the therapeutic administration of pharmacological agents used to 
treat motivational dysfunction and psychomotor challenges. 
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